Thompson A. A much-needed focus on progression in multiple sclerosis. The Lancet Neurology, 2015, 14(2): 133-135. doi: 10.1016/s1474-4422(14)70330-8..
DOI: 10.1016/s1474-4422(14)70330-8
Leary S, Miller D, Stevenson V, Brex P, Chard D, Thompson A. Interferon В-1a in primary progressive MS: An exploratory, randomized, controlled trial. Neurology, 2003, 60(1): 44-51. doi: 10.1212/wnl.60.1.44..
DOI: 10.1212/wnl.60.1.44
Montalban X, Sastre-Garriga J, Tintore M et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Multiple Sclerosis, 2009, 15(10): 1195-1205. doi: 10.1177/1352458509106937..
DOI: 10.1177/1352458509106937
Wolinsky J, Narayana P, O’Connor P et al. Glatira-mer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Annals of Neurology, 2007, 61(1): 14-24. doi: 10.1002/ana.21079..
DOI: 10.1002/ana.21079
Lublin F, Miller D, Freedman M et al. Oral fin-golimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. The Lancet, 2016, 387(10023): 1075-1084. doi: 10.1016/ s0140-6736(15)01314-8..
DOI: 10.1016/ s0140-6736(15)01314-8
Hawker K, O’Connor P, Freedman M et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Annals of Neurology, 2009, 66(4): 460-471. doi: 10.1002/ana.21867..
DOI: 10.1002/ana.21867
Hohlfeld R, Meinl E. Ocrelizumab in multiple sclerosis: markers and mechanisms. The Lancet Neurology, 2017, 16(4): 259-261. doi: 10.1016/ s1474-4422(17)30048-0..
DOI: 10.1016/ s1474-4422(17)30048-0
Hauser SL, Bar-Or A, Comi G et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. The New England Jour of Med, 2017, 376(3): 209-220. doi: 10.1056/NEJMoa1601277..
DOI: 10.1056/NEJMoa1601277
Montalban X, Hauser SL, Kappos L et al. Ocreli zumab versus Placebo in Primary Progressive Multiple Sclerosis. The New England Jour of Med, 2017, 376(3): 1-14. doi: 10.1056/NEJMoa1606468..
DOI: 10.1056/NEJMoa1606468